Table 1.
Baseline demographics
| Hypo-responders (n = 36) | Responders (n = 25) | p value | |
|---|---|---|---|
| Age (years) | 62.4 ± 2.24 | 62.6 ± 2.38 | 0.97 |
| Male sex (%) | 10 (27.8) | 7 (28.0) | 1 |
| PRU | 262.4 ± 7.36 | 142.1 ± 8.59 | < 0.01 |
| ARU | 489.1 ± 11.7 | 482.5 ± 16.1 | 0.73 |
| Body mass index | 22.5 ± 0.61 | 22.3 ± 0.61 | 0.85 |
| Smoking (%) | 9 (25.0) | 6 (24.0) | 1 |
| Previously treated aneurysms (%) | 5 (13.9) | 5 (20.0) | 0.73 |
| Blood sample | |||
| Hb (mg/dl) | 13.1 ± 0.22 | 13.5 ± 0.29 | 0.31 |
| Platelet (104/μL) | 21.9 ± 0.99 | 24.8 ± 1.27 | 0.08 |
| PT-INR | 0.94 ± 0.01 | 0.92 ± 0.01 | 0.42 |
| comorbidities | |||
| Hypertension (%) | 19 (52.8) | 20 (76.0) | 0.11 |
| Diabetes mellitus (%) | 0 | 2 (8.0) | 0.16 |
| Hyperlipidemia (%) | 15 (41.7) | 17 (64.0) | 0.12 |
| Chronic renal failure (%) | 5 (13.89) | 3 (12.0) | 1 |
Continuous variables are presented as average (mean ± SE). Categorical variables are presented as number of patients (percentage). PRU P2Y12 Reaction Units; ARU Aspirin Reaction Units; Hb Hemoglobin; PT-INR prothrombin time international normalized ratio